Related Experiment Videos
The clinical significance of neurohormonal activation
1Reno Cardiology Research Laboratory, Nevada, USA.
Insights
Neurohormonal activation, not just hemodynamic factors, drives progressive heart disease. Understanding this interaction is key to optimizing cardiovascular pharmacologic therapy for better patient outcomes.
Area of Science:
- Cardiovascular Medicine
- Heart Failure Pathophysiology
Background:
- Progressive heart disease is often linked to hemodynamic changes post-left ventricular dysfunction.
- Compensatory mechanisms can increase stress on a failing heart.
- Pharmacologic therapy maintaining hemodynamics doesn't always halt heart failure progression.
Purpose of the Study:
- To investigate the role of neurohormonal systems in chronic heart failure progression.
- To understand the interplay between neurohormonal activation and hemodynamic factors.
- To identify targets for optimizing cardiovascular pharmacologic therapy.
Main Methods:
- The study reviews existing literature on hemodynamic and neurohormonal mechanisms in heart failure.
- It analyzes the effects of neurohormonal activation on left ventricular remodeling and function.
- It discusses the implications for pharmacologic interventions.
Main Results:
- Neurohormonal systems, beneficial in acute heart failure, have deleterious effects in chronic stages.
- Chronic activation increases left ventricular load and promotes detrimental structural remodeling.
- Neurohormonal activation correlates with heart failure severity.
Conclusions:
- Neurohormonal activation plays a critical pathogenic role in progressive heart disease.
- Interventions with favorable hemodynamics but unfavorable neurohormonal effects can worsen outcomes.
- Optimizing therapy requires understanding neurohormonal effects alongside hemodynamic ones.
Abstract:
Progressive heart disease after the onset of left ventricular dysfunction has typically been attributed to hemodynamic factors. As left ventricular function declines, decreased cardiac output and tissue hypoperfusion lead to compensatory increases in afterload, preload, and heart rate. The purpose of these compensatory responses is to increase cardiac output and maintain tissue perfusion; however, they may also create hemodynamic stress for the failing heart. However, this does not explain the progression of heart failure despite hemodynamic maintenance with pharmacologic therapy. Activation of neurohormonal systems that are essential for homeostasis in the normal heart plays a key role in the progression of heart failure. In acute heart failure, these systems have beneficial effects, but in chronic heart failure their activation produces deleterious effects by increasing the load on the left ventricle and promoting structural remodeling, which may further impair left ventricular function. The issue of neurohormonal activation is an important one in cardiovascular medicine, not only for patients with heart failure but also for patients with hypertension and ischemic heart disease when left ventricular dysfunction is present. As neurohormonal activation may play a pathogenic role in the long-term outcome of patients, interventions that have favorable hemodynamic but unfavorable neurohormonal effects can actually exacerbate cardiac disease and may increase cardiovascular morbidity and mortality. As neurohormonal activation appears to parallel the severity of heart failure, whether assessed according to symptoms or prognosis, an understanding of neurohormonal activation and its interaction with hemodynamic factors is essential for optimizing pharmacologic therapy for cardiovascular disease.